Source:http://linkedlifedata.com/resource/pubmed/id/12594695
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2003-2-20
|
| pubmed:abstractText |
Conventional interventional therapy has been less rewarding in chronic total occlusion (CTO). Brachytherapy by its antiproliferative and positive remodeling effect may be more efficacious. Forty-six centers registered 1,098 consecutive patients undergoing brachytherapy with the BetaCath system. Of these, 78 patients had 82 lesions (CTO) at presentation-the study population. With 67% in-stent CTO, 8% graft CTO, 4% recurrent CTO, long lesions (27.6 +/- 20.9 mm), and 31% diabetes, the cohort had high risk for recurrence. The in-hospital event rate was 1.3%. Six-month follow-up revealed 1.3% death, 5.1% myocardial infarction, 21.8% target vessel revascularization, 77.8% improved angina, 34.5% binary restenosis, 12.7% reocclusion, and 10.3% late thrombosis. The results were comparable to all other patients in the registry, although late thrombosis rate was higher in the CTO group (10.3% vs. 5.0%; P = 0.047). In the in-stent CTO subgroup (n = 52; 66.7%), there was no in-hospital event, no follow-up death or myocardial infarction, restenosis in 35.1%, and reocclusion in 10.8% of patients. In comparison, death or myocardial infarction was significantly higher in de novo CTO subgroup (P = 0.005). Compared to all other in-stent restenosis patients in the registry, the patients with in-stent CTO had similar clinical and angiographic event rate. Thus, beta-brachytherapy was safe, feasible, and effective in this broad population of high-risk patients with CTO presenting in day-to-day practice. It was particularly effective in in-stent CTO, where conventional interventional strategies are disappointing.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1522-1946
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2003 Wiley-Liss, Inc.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
58
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
322-9
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:12594695-Aged,
pubmed-meshheading:12594695-Beta Particles,
pubmed-meshheading:12594695-Brachytherapy,
pubmed-meshheading:12594695-Chronic Disease,
pubmed-meshheading:12594695-Cohort Studies,
pubmed-meshheading:12594695-Coronary Angiography,
pubmed-meshheading:12594695-Coronary Restenosis,
pubmed-meshheading:12594695-Coronary Stenosis,
pubmed-meshheading:12594695-Feasibility Studies,
pubmed-meshheading:12594695-Female,
pubmed-meshheading:12594695-Follow-Up Studies,
pubmed-meshheading:12594695-Graft Occlusion, Vascular,
pubmed-meshheading:12594695-Humans,
pubmed-meshheading:12594695-Male,
pubmed-meshheading:12594695-Middle Aged,
pubmed-meshheading:12594695-Outcome Assessment (Health Care),
pubmed-meshheading:12594695-Risk Factors,
pubmed-meshheading:12594695-Severity of Illness Index
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Intracoronary beta-brachytherapy in chronic total occlusions: a subgroup analysis from the RENO registry.
|
| pubmed:affiliation |
Medizinische Klinik II, Universitätsklinikum Lübeck, Lübeck, Germany. deepakjain@hotmail.com
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|